<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147923">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823887</url>
  </required_header>
  <id_info>
    <org_study_id>C-01</org_study_id>
    <nct_id>NCT01823887</nct_id>
  </id_info>
  <brief_title>Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study</brief_title>
  <acronym>ANTHEM-HF</acronym>
  <official_title>Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ANTHEM-HF Study is designed to demonstrate the safety and efficacy of vagus nerve
      stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with
      symptomatic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure patients will be enrolled and randomized to cervical VNS implantation on
      either the left side or right side. After a 2-week post-implantation recovery period and a
      10-week stimulation titration period, continuous periodic stimulation will be performed for
      6 months, with data collection at 3 months and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Left ventricular end-systolic volume (LVESV), left ventricular end-systolic diameter (LVESD), and ejection fraction (EF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of procedure and device-related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>New York Heart Association Class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic Function</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heart Rate Variability (HRV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Biomarkers</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood Levels of Heart Failure Biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Left Sided Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left cervical Vagus Nerve Stimulation (VNS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Right Sided Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right Cervical Vagus Nerve Stimulation (VNS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagus Nerve Stimulation (VNS)</intervention_name>
    <description>Electrical Stimulation of the Vagus Nerve</description>
    <arm_group_label>Left Sided Stimulation</arm_group_label>
    <arm_group_label>Right Sided Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic heart failure, New York Heart Association (NYHA) class
             II/III with reduced EF and dilated hearts
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imad Libbus, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cyberonics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Vagus Nerve</keyword>
  <keyword>VNS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
